title: Visceral leishmaniasis infection during adalimumab therapy: a case report and literature review.
authors: Department of Internal Medicine, University and Polytechnic Hospital of la Fe, Valencia, Spain.
authors: Yale
authors: Y
authors: Tung Chen
authors: Carolina
authors: C
authors: Perales
authors: Jose
authors: J
authors: Lacruz
authors: Leonor
authors: L
authors: Senent
authors: Miguel
authors: M
authors: Salavert
mesh_terms: D000068879:Adalimumab; D000368:Aged; D000666:Amphotericin B / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D001856:Bone Marrow Examination; D057915:Drug Substitution; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D007898:Leishmaniasis, Visceral / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology / Q000469:parasitology; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D011237:Predictive Value of Tests; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000981:Antiprotozoal Agents; D018501:Antirheumatic Agents; D005938:Glucocorticoids; C068538:liposomal amphotericin B; D000666:Amphotericin B; D000068879:Adalimumab; D008775:Methylprednisolone